For US Healthcare Professionals only

HemAssist logo

Patient support for ELOCTATE®

HemAssist complements the care you provide your patients with support for what’s ahead.


Getting started with ELOCTATE

HemAssist works with you and your patients to get them started on ELOCTATE as efficiently as possible. Our support begins with the enrollment process. As soon as we receive an enrollment form, we can begin a benefits investigation to determine if your patient is eligible for financial assistance.

Our support includes triaging the prescription to the patient's specialty pharmacy and assisting with medication shipments, providing patients with supplemental infusion training, supporting patients with claims and reimbursements, and more.

Eloctate product logo

Our support

Decorative wallet icon

Affording ELOCTATE

No matter your patient's situation, we are committed to helping them access and afford ELOCTATE. The HemAssist team will verify your patient's insurance coverage and determine what financial assistance programs they may be eligible for.

Decorative 1-2-3 steps icon

Starting treatment

The HemAssist team can help your patient get started with ELOCTATE right away. We can provide supplemental infusion training and offer tips for building a treatment routine.

Decorative conversation bubble icon

Ongoing support

Our team provides support and guidance to your patient throughout the ELOCTATE journey. This includes navigating insurance changes and periodically checking with the patient to support them throughout treatment.

Financial assistance

HemAssist works directly with your patients to help identify programs they may be eligible for.

Copay Assistance Program*

HemAssist may be able to help eligible patients gain access to ELOCTATE for as little as $0.

Free Trial Program†

With the Free Trial Program, patients can get their first 30-day supply of treatment generally within 24 to 48 hours with a valid prescription. While you and your patient are deciding what treatment is right for them, a dedicated Sanofi Case Manager will review their health insurance information and coverage for ELOCTATE. Once the enrollment is complete, a dedicated Sanofi Case Manager will contact your patient within 24 hours with next steps.

Patient Assistance Program†

HemAssist's Patient Assistance Program may be available to help eligible ELOCTATE patients who are uninsured, underinsured, or experiencing a temporary loss of insurance coverage.

*Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their ELOCTATE prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their ELOCTATE prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

† Free Trial valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free Trial not valid in Vermont. Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Meet your team

HemAssist works directly with your patients to help identify programs they may be eligible for.

HemAssist team member sitting at a desk with a headset

Clinical Educator (CE)

CEs can answer questions from you or your patients about ELOCTATE and can provide patients with helpful support including treatment tips and supplemental administration training.

Portrayal of a smiling man sitting at a desk wearing a headset

Case Managers

Case Managers provide you with personalized insurance investigations and answer questions about financial assistance options for eligible patients. They can help coordinate treatment shipments and assist with reimbursements.

Portrayal of an woman in an office speaking into a headset

Field Reimbursement Managers (FRM)

Our FRMs can navigate insurance coverage and provide reimbursement education and solutions on behalf of patients.

Ready to enroll a patient in HemAssist?

It takes just a few steps. Enroll online or download and fax an enrollment form. 

INDICATION

ELOCTATE is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

LIMITATION OF USE

ELOCTATE is not indicated for the treatment of von Willebrand disease.

 

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.

WARNINGS AND PRECAUTIONS

  • Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. Immediately discontinue ELOCTATE and initiate appropriate treatment if hypersensitivity reactions occur.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ELOCTATE. Patients using ELOCTATE should be monitored for the development of Factor VIII inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor VIII levels have been achieved and maintained.
  • Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.
  • If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteremia, and catheter-site thrombosis should be considered.

ADVERSE REACTIONS

The most frequently occurring adverse reactions (incidence >0.5% of subjects) reported in previously treated patients (PTPs) clinical trials were arthralgia, malaise, myalgia, headache, and rash. The most frequently occurring adverse reactions (incidence ≥1.0% of subjects) reported in previously untreated patients (PUPs) clinical trials were Factor VIII inhibition, device-related thrombosis, and rash papular.

INDICATION

IMPORTANT SAFETY INFORMATION

HemAssist Sanofi Support Here for your patients throughout their treatment journey. Call 1-833-723-5463 Monday – Friday 8 AM to 7 PM ET Fax 1-855-398-7634 © 2025 Sanofi. All rights reserved. ELOCTATE, HemAssist, and Sanofi are trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2505188-v1.0-08/2025